Grease composition with medical post-art repair effect and application thereof

Abstract

The invention provides an application of a grease composition containing safflower seed oil, fermented artemisia apiacea oil and selaginella oil in post-medical repair. The fermented artemisia apiacea oil is prepared by the following steps: (a) carrying out supercritical CO2 extraction on artemisia apiacea medicinal materials; (b) fermenting, namely fermenting by adopting bifidus yeast; (c) separating to obtain fermented artemisia apiacea oil; wherein the bifidobacterium is selected from bifidobacterium adolescentis, bifidobacterium animalis subspecies, bifidobacterium animalis subspecies lactis, bifidobacterium bifidum, bifidobacterium breve, bifidobacterium longum subspecies longum or bifidobacterium longum subspecies infantis. The medical art is caused by dot matrix laser. The invention further relates to application of the grease composition containing the safflower seed oil, the fermented artemisia apiacea oil and the selaginella oil in preparation of an external skin preparation with a post-medical repair effect.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of cosmetics, in particular to an oil composition with post-medical-beautifying repair effect and application thereof. BACKGROUND

[0002] China has abundant resources of Chinese herbal medicines, and many research reports have shown that cosmetic raw materials with significant skin care effects can be obtained by microbial fermentation of Chinese herbal medicines. However, the research on the fermentation of Artemisia annua is limited.

[0003] Artemisia annua L. is a traditional Chinese medicine, which was first recorded in the Fifty-two Prescriptions, and was later included in many herbal classics. It is widely distributed in Chongqing, Anhui, Hubei, Shandong and other places in China. As a traditional Chinese medicine, Artemisia annua is mainly used to treat fever and cold, and is recorded in Shennong's Herbal Classic, Elbow Post Emergency Prescriptions and Compendium of Materia Medica. Artemisia annua has the effects of clearing heat and resolving toxins, cooling blood and invigorating the stomach. It contains flavonoids, polysaccharides, polyphenols, volatile oils and other bioactive components.

[0004] Fermented Artemisia annua oil is made from traditional antimalarial herb Artemisia annua, and after fermentation, the liposoluble active ingredients such as artemisinin derivatives and terpenoids are significantly increased. At the same time, the secondary metabolites generated during the fermentation process can enhance the anti-inflammatory and antibacterial activities.

[0005] Red safflower seed oil is derived from the seeds of Carthamus tinctorius L. of the Asteraceae family. After extraction, it can retain a high concentration of linoleic acid, which is not only an important component of skin barrier lipids, but also can improve water retention capacity by regulating the arrangement of stratum corneum lipids. However, existing research lacks molecular evidence on the regulation of lipid metabolism in skin damage.

[0006] Selaginella tamariscina (Beauv.) Spring and Selaginella pulvinata (Hook. et Grev.) Maxim are the dried whole grass of Selaginella tamariscina (Beauv.) Spring of the fern family Selaginellaceae, which belongs to perennial herbaceous plants. The 2020 edition of the Pharmacopoeia has included Selaginella tamariscina and Selaginella pulvinata as the specified varieties of Selaginella tamariscina. Selaginella tamariscina, Selaginella pulvinata and their congeneric plants are widely distributed and have many varieties, with more than 70 species in China.

[0007] The chemical components of Selaginella plants are diverse, and the main chemical components are flavonoids, followed by alkynyl phenols, lignans, steroids, alkaloids, and anthraquinones. Modern pharmacological and clinical studies have shown that Selaginella plants not only have traditional anti-inflammatory and detoxification effects, but also have antibacterial, antiviral, immune-enhancing, antitumor, sedative and analgesic, and hypoglycemic effects.

[0008] The present application first explores the repair effect of the combination of fermented artemisia oil, safflower seed oil, and selaginella oil after, for example, fractional laser surgery, and its application in cosmetic compositions. SUMMARY

[0009] In one aspect, the present application provides an oil composition comprising safflower seed oil, fermented artemisia oil, and selaginella oil for post-medical cosmetic repair application, wherein the fermented artemisia oil is prepared by the following method:

[0010] (a) using artemisia medicinal materials for supercritical CO2 extraction;

[0011] (b) fermentation, using bifida fermentation;

[0012] (c) obtaining fermented artemisia oil after separation;

[0013] wherein the bifida is selected from Bifidobacterium adolescentis, Bifidobacterium animalis subsp. animalis, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum subsp. longum, or Bifidobacterium longum subsp. infantis.

[0014] In a preferred embodiment, the content of artemisinic acid in the fermented artemisia oil is ≥0.03% by weight, the acid value of the fermented artemisia oil is ≤2.5 mg / g, the peroxide value of the fermented artemisia oil is ≤0.650 g / 100 g, and the density of the fermented artemisia oil is 0.9-0.95 g / cm 3 .

[0015] In a preferred embodiment, the weight ratio of safflower seed oil: fermented artemisia oil: selaginella oil in the oil composition is 1000-2000: 1000-2000: 1.

[0016] In a preferred embodiment, the post-medical cosmetic procedure is caused by fractional laser.

[0017] In a preferred embodiment, the repair includes reducing the skin TEWL change after the medical cosmetic procedure.

[0018] In another aspect, the present application also relates to the use of an oil composition comprising safflower seed oil, fermented artemisia oil, and selaginella oil in the preparation of a skin external agent with post-medical cosmetic repair effect, wherein the fermented artemisia oil is prepared by the following method:

[0019] (a) Artemisia argyi crude drug is extracted by supercritical CO2;

[0020] (b) fermentation, using Schizochytrium sp. for fermentation;

[0021] (c) after separation, fermented Artemisia argyi oil is obtained;

[0022] wherein the Schizochytrium sp. is Bifidobacterium, selected from the group consisting of Bifidobacterium adolescentis, Bifidobacterium animalis subsp. animalis, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum subsp. longum, and Bifidobacterium longum subsp. infantis.

[0023] In a preferred embodiment, the weight ratio of safflower seed oil: fermented Artemisia argyi oil: Selaginella oil in the oil composition is 1000-2000: 1000-2000: 1.

[0024] In a preferred embodiment, the content of the oil composition in the skin external preparation is 0.001-100% by weight, preferably 0.01-5% by weight.

[0025] In a preferred embodiment, the skin external preparation is selected from the group consisting of a cream, a lotion, a gel, a toner, an essence, a mask, an eye cream, an aerosol cleansing foam, a spray, a shower gel, and a facial cleanser. BRIEF DESCRIPTION OF DRAWINGS

[0026] Figure 1 The results of the change in TEWL of mice evaluated using GPSkin equipment for 12 hours are shown. 12h after the dot laser, the TEWL of the back skin of mice in the dot laser group increased significantly, and sample 1, sample 2, sample 4, sample 5, and sample 6 all had the effect of alleviating the increase in TEWL caused by the dot laser, indicating that the samples had the effect of promoting repair after the dot laser.

[0027] Figure 2 The results of the change in TEWL of mice evaluated using GPSkin equipment for 24 hours are shown. 24h after the dot laser, the TEWL of the back skin of mice in the dot laser group increased significantly, and sample 1, sample 2, sample 4, sample 5, and sample 6 all had the effect of alleviating the increase in TEWL caused by the dot laser, and sample group 2 and sample group 5 and sample group 6 were relatively optimal.

[0028] Figure 3 The results of the change in TEWL of mice evaluated using GPSkin equipment for 36 hours are shown. 36h after the dot laser, the TEWL of the back skin of mice in the dot laser group increased significantly, and sample 1, sample 2, sample 4, sample 5, and sample 6 all had the effect of alleviating the increase in TEWL caused by the dot laser, and sample group 2 and sample group 5 and sample group 6 were relatively optimal.

[0029] Figure 4The results of the change of TEWL of mice evaluated using GPSkin device for 48 hours are shown. 18h after the dot laser, the TEWL of the back skin of mice in the dot laser group increased significantly, and sample 1, sample 2, sample 4, sample 5, sample 6 all had the effect of alleviating the increase of TEWL caused by dot laser, indicating that the samples had the effect of promoting repair after dot laser.

[0030] Figure 5 The results of the change of TEWL of mice evaluated using GPSkin device for 5 days are shown. 5 days after the dot laser, the TEWL of the back skin of mice in the dot laser group increased significantly, and sample 1, sample 2, sample 4, sample 5, sample 6 all had the effect of alleviating the increase of TEWL caused by dot laser, indicating that the samples had the effect of promoting repair after dot laser.

[0031] Figure 6 The results of the change of TEWL of mice evaluated using GPSkin device for 7 days are shown. 7 days after the dot laser, the TEWL of the back skin of mice in the dot laser group increased significantly, and sample 1, sample 2, sample 4, sample 5, sample 6 all had the effect of alleviating the increase of TEWL caused by dot laser, and sample 5 was the best.

[0032] Figure 7 The results of the mice photographed on the 1st-3rd day after the dot laser and the application of butyl butyrate or Tween 20 are shown. The results show that butyl butyrate has no skin repair effect on the skin of the mouse dot laser model, nor does it have the effect of damaging the barrier.

[0033] Figure 8 The results of the change of TEWL of mice evaluated using GPSkin device for 1-3 days after the dot laser and the application of butyl butyrate or Tween 20 are shown. The results show that butyl butyrate has no effect on alleviating the increase of transdermal water loss on the skin of the mouse dot laser model. DETAILED DESCRIPTION

[0034] It is found for the first time that the oil composition of fermented artemisia oil, safflower seed oil and selaginella oil obtained by fermenting artemisia oil with two-row yeast as a strain has a skin repair effect after dot laser, and is particularly suitable for preparing a cosmetic composition with a skin repair effect.

[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, the preferred methods and materials are described. For the purposes of the present application, the following terms are defined below.

[0036] As used herein, the term "about" means an amount, level, value, dimension, size or quantity that varies by as much as 30%, or as much as 20%, or as much as 10% to a reference amount, level, value, dimension, size or quantity. Percentages used herein are by weight unless otherwise specified.

[0037] Throughout this specification and claims, unless the context requires otherwise, the word "comprise," and variations such as "comprises" and "comprising," will be understood to mean the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0038] Oil composition

[0039] The present application provides a lipid composition comprising safflower seed oil and fermented artemisia oil.

[0040] The fermented artemisia oil used in the present application is purchased from Hangzhou Shiguang Xinya Biotechnology Co., Ltd. The artemisia oil used in the present application is obtained by fermentation of artemisia medicinal materials using two-row yeast as a strain. In this application, four different batches of fermented artemisia oil are used for experiments, namely fermented artemisia oil batch 1, fermented artemisia oil batch 2, fermented artemisia oil batch 3, and fermented artemisia oil batch 4.

[0041] The fermented artemisia oil used in the present application is obtained by supercritical CO2 extraction and fermentation of artemisia medicinal materials using two-row yeast. The two-row yeast strain is Bifidobacterium bifidum, including Bifidobacterium adolescentis, Bifidobacterium animalis subsp. Animalis, Bifidobacterium animalis subsp. Lactis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum subsp. Longum, and Bifidobacterium longum subsp. infantis.

[0042] In a specific embodiment, the content of artemisinic acid in the fermented artemisia oil of the present application is ≥0.03% by weight, the acid value of the fermented artemisia oil is ≤2.5 mg / g, the peroxide value of the fermented artemisia oil is ≤0.650 g / 100 g, and the density of the fermented artemisia oil is 0.9-0.95 g / cm 3 .

[0043] In embodiments of the present invention, the fatty acid composition of the fermented artemisia annua oil is greater than 90% by weight. In embodiments of the present invention, the relative content of linoleic acid in the fatty acid composition of the fermented artemisia annua oil is ≥35% by weight, preferably ≥45% by weight.

[0044] In an embodiment of the present invention, the content of artemisinin in the fermented artemisia oil is ≥0.03% by weight, preferably ≥0.05% by weight.

[0045] GC-MS analysis of fermented artemisia annua oil revealed a total of 54 compounds, including lipids, aldehydes, terpenes, sterols, vitamins, and others. Mass content analysis showed that fatty acid glycerides were the dominant compounds (93.4%-99.4%), with other trace components including squalene (0.01%-0.02%), vitamin E (0.02%-0.04%), and γ-sitosterol (0.08%-0.14%). Further relative mass content analysis revealed three aldehydes, including 2-heptenal, trans-2-decenal, and a high content of trans-2,4-decadienal (7.38%); six terpenoids, represented by β-caryophyllene (8.97%), β-serlingene, and caryophyllin; and three sterols, with γ-sitosterol (6.52%), campesterol (10.11%), and stigmasterol (5.36%) forming the sterol system. Vitamin E (3.99%) was the only vitamin component detected. Notably, the triterpenoid cycloartenol was the most abundant component at 40.27%, while α-amyrin and 24-methylenecycloartenol further enriched the diversity of terpenoids. Other components included organic acids such as hydroxyvaleric acid and sesquiterpene lactones such as artemisinin b (1.53%), collectively forming a complex component system.

[0046] In addition, fermented artemisia annua oil contains dozens of fatty acids. The saturated fatty acids are mainly palmitic acid (C16:0, 5.87%), stearic acid (C18:0, 3.49%), and behenic acid (C22:0, 0.749%). Oleic acid (C18:1n9c, 26.1%) is the dominant monounsaturated fatty acid. Among polyunsaturated fatty acids, linoleic acid (C18:2n6c, 53%) is the most abundant component, followed by α-linolenic acid (C18:3n3, 0.11%), while γ-linolenic acid (C18:3n6) is present in low amounts (≤0.0026%). Furthermore, trace amounts of long-chain fatty acids such as arachidic acid (C20:0, 0.259%) and lignotaric acid (C24:0, 0.259%) were also detected in the fatty acid glycerides.

[0047] Safflower seed oil was purchased from Shanghai Zhongrui Biotechnology Co., Ltd., under the trade name Carthamus tinctorius seed oil. GC-MS analysis identified 42 characteristic compounds, including lipids, aldehydes, and terpenes. Lipid components were mainly glycerol derivatives, with 2-linoleylglycerol monoester (57.10%) being the most abundant, followed by glyceryl trilinoleate (19.54%) and ethyl linoleate (5.33%). Other structurally diverse components, such as free fatty acid linoleic acid (5.28%) and glycidyl palmitate (4.11%), were also detected. Aldehydes were mainly trans-2,4-decadienal (0.99%) and 2,4-decadienal (0.70%), while only betulinol (1.69%) was detected among terpenes. In addition, trace components such as 1,2-dipalmitin (0.56%) and glyceryl monooleate (0.37%) further enriched the complexity of the lipid profile, indicating that the lipid composition of safflower seed oil is centered on high content of glycerides, and has both structural complexity and potential functional characteristics.

[0048] Further analysis of its fatty acids showed that the fatty acid composition of safflower seed oil exhibited significant unsaturated characteristics, with linoleic acid (C18:2n6c) accounting for 69.1%, and together with oleic acid (C18:1n9c, 18.7%), forming a total unsaturated fatty acid system of 88.7%, while also containing a small amount of the essential fatty acid α-linolenic acid (Table 3-1-1-2).

[0049] The raw herb used, Selaginella tamariscina (Beauv.) Spring, was purchased in May 2023 from Xingzhi Pharmacy in the Hehuachi Traditional Chinese Medicine Market in Sichuan Province. It is the dried whole herb of Selaginella tamariscina (Beauv.) Spring, a plant of the Selaginellaceae family.

[0050] The Selaginella oil described in this invention can also be described as Selaginella volatile oil. The Selaginella volatile oil is extracted using supercritical fluid extraction. Preferably, this invention uses CO2 supercritical extraction to obtain the effective components of Selaginella, and then obtains the Selaginella volatile oil (decolorized) through filtration, decolorization, and concentration.

[0051] In some embodiments, supercritical fluid extraction is used to extract volatile oil from Selaginella tamariscina, including the following steps:

[0052] (a) Provide Selaginella, mechanically pulverized;

[0053] (b) Add ethanol and mix.

[0054] (c) Perform supercritical fluid extraction at an extraction pressure of 20-25 MPa and an extraction temperature of 40-45℃;

[0055] (d) Collect the extract and let it stand at a low temperature;

[0056] (e) Centrifuge, collect the supernatant, and filter;

[0057] (f) Decolorization;

[0058] (g) The filtrate was concentrated to extract state to obtain Selaginella tamariscina volatile oil (decolorized).

[0059] In some embodiments, the extraction method includes the step of pulverizing the medicinal material to a mesh size of 20-40. In some embodiments, the extraction method includes the step of mixing the material with ethanol. In a preferred embodiment, 75-95% by volume of ethanol is used for mixing. In some embodiments, the extraction method includes an extraction pressure of 20-25 MPa. In some embodiments, the extraction method includes an extraction temperature of 40-45°C. In some embodiments, the extraction method includes a CO2 flow rate of 75-85 L / h, for example, 80 L / h. In some embodiments, the extraction method includes an extraction time of 60-120 min, for example, about 90 min.

[0060] In a preferred embodiment, the process parameters for supercritical fluid extraction are as follows: the medicinal material is pulverized to 20 mesh, the extraction pressure is 20-25 MPa, the extraction temperature is 40-45℃, the CO2 flow rate is 80-85 L / h, and the supercritical extraction time is approximately 90-120 min.

[0061] In a preferred embodiment, the process parameters for supercritical fluid extraction include: pressure of separation vessel I is 8-9 MPa, and temperature of separation vessel I is 40-45℃; pressure of separation vessel II is 6-7 MPa, and temperature of separation vessel II is 30-35℃; pressure of separation vessel III is 6-7 MPa, and temperature of separation vessel III is 30-35℃.

[0062] In a preferred embodiment, the low-temperature settling in step (d) includes settling at 0-6°C for 12-24 hours.

[0063] In a preferred embodiment, activated carbon is used for decolorization, for example, 1.5 wt% activated carbon is used for decolorization. The resulting Selaginella tamariscina volatile oil (decolorized) is a deep yellow solid oily substance.

[0064] In a preferred embodiment, the total sugar content of the Selaginella tamariscina volatile oil is ≥14.99 wt%, the total polyphenol content is ≥2.13 wt%, and / or the total flavonoid content is ≥4.97 wt%.

[0065] Skin external preparation

[0066] The oil composition of the present invention can be used as an efficacy additive in topical skin agents to improve skin condition.

[0067] In some embodiments, the oil composition is present in the topical skin agent at a concentration of 0.001-20% by weight, preferably 0.01-5% by weight.

[0068] In some embodiments, the concentration of the oil composition used is at least 0.01% by weight. In some embodiments, the concentration of the oil composition used is 0.01-1% by weight, preferably 0.01-0.5% by weight. In preferred embodiments, the concentration of the oil composition used is 0.02-0.25% by weight. In some embodiments, the concentration of the oil composition used is 0.02-0.1% by weight. In specific embodiments, the concentration of the oil composition used is 0.03% by weight. In some embodiments, the concentration of the oil composition used is 0.1-0.25% by weight.

[0069] In some embodiments, the topical skin agent is selected from: face creams, lotions, gels, toners, serums, face masks, eye creams, aerosols (cleansing foams), shower gels, and facial cleansers. Different dosages are added depending on the type of formulation.

[0070] The term "topical skin agent" is a general term encompassing all ingredients typically used on the external surface of the skin, such as cosmetic compositions. These cosmetic compositions can include basic cosmetics, facial makeup cosmetics, body cosmetics, hair care cosmetics, etc., with no specific restrictions on their dosage forms; they can be rationally selected according to different purposes. Depending on the dosage form and purpose, these cosmetic compositions may also contain different cosmetically permissible media or matrix excipients.

[0071] Topical skin preparations contain dermatologically acceptable carriers or mediators (e.g., lotions, creams, ointments, cleansers, etc.). Those skilled in the art can select carriers capable of dissolving or dispersing these components at the concentrations described above, based on common knowledge in the art. When using a carrier, it should not cause inactivation of the oil-based composition and should not produce any adverse effects on the skin during application.

[0072] Those skilled in the art can select suitable carriers based on common knowledge and their ability to dissolve or disperse in the active component at the concentration most suitable for processing, such as water, alcohols, oils, etc.

[0073] The topical skin agents of the present invention can be in the form of topical application products that can be applied externally to the skin and can be prepared using common techniques known in the art. The carrier can have various practical forms, such as creams, dressings, gels, lotions, ointments, or liquids, including compositions that are applied and washed off, and materials incorporated into them using methods known in the art, such as dry or wet applicators, hydrogel matrices, or adhesive (or non-adhesive) patches. Preferably, the carrier is a gel or a moisture-enhancing lotion, or an applicator in dry or wet form.

[0074] Typical carriers include emulsions containing water and / or alcohols and emollients, where the emollients are, for example, oils and waxes of hydrocarbons, silicone oils, hyaluronic acid, fats or oils from plants, animals, or marine organisms, glyceryl ester derivatives, fatty acids, or fatty acid esters or alcohols or alcohol ethers, lanolin and its derivatives, polyols or esters, wax esters, sterols, phospholipids, etc., and generally include emulsifiers (nonionic, cationic, or anionic), although some emollients themselves have emulsifying properties. Additionally, these same components can be formulated into creams, gels, or solid bars by utilizing different proportions of their components and / or by incorporating thickeners such as gums or other forms of hydrophilic colloids.

[0075] The topical skin formulation of the present invention may include additional components commonly found in skin care compositions, such as emollients, skin conditioners, emulsifiers, preservatives, antioxidants, fragrances, chelating agents, etc., provided that they are physically and chemically compatible with other components in the topical skin formulation and do not affect the efficacy of the oil composition of the present invention.

[0076] In some embodiments of the topical skin formulation of the present invention, one or more preservatives may be used. Suitable preservatives include p-hydroxyacetophenone, C1-C4 alkyl p-hydroxybenzoate, and phenoxyethanol. Based on the total weight of the composition, the amount of preservative used is from about 0.5 to about 2% by weight, preferably from about 0.5 to 1% by weight.

[0077] In one example of the topical skin formulation of the present invention, one or more antioxidants may be used. Suitable antioxidants include butylated hydroxytoluene (BHT), ascorbyl palmitate (BHA), butylated hydroxyanisole, phenyl-α-naphthylamine, hydroquinone, propyl gallate, nordihydroguaiac acid, vitamin E or a derivative of vitamin E, vitamin C and its derivatives, calcium pantothenate, green tea extract, and mixed polyphenols, as well as mixtures of the substances described above. The antioxidant used is approximately 0.02 to 0.5% by weight of the total weight of the composition, more preferably in the range of approximately 0.002 to 0.1% by weight.

[0078] In one example of the topical skin formulation of the present invention, one or more emollients may be used, which, by virtue of their ability to remain on the skin surface or in the stratum corneum, act as lubricants to reduce exfoliation and improve the appearance of the skin. Typical emollients include fatty esters, fatty alcohols, mineral oils, polyether silicone copolymers, and the like. Examples of suitable emollients, not limited to, include polypropylene glycol (“PPG”)-15 octadecyl ether, PPG-10 hexadecyl ether, Steareth-10, Oleth-8, PPG-4 dodecyl ether, vitamin E acetate, lanolin, cetyl alcohol, cetearyl alcohol ethylhexanoate, cetearyl alcohol, glyceryl stearate, octyl hydroxystearate, dimethyl polysiloxane, and combinations thereof. Cetyl alcohol, cetearyl alcohol ethylhexanoate, cetearyl alcohol, glyceryl stearate, and combinations thereof are preferred. When used, the emollient is applied in an amount ranging from about 0.1% to about 30% by weight, preferably from about 1% to about 30% by weight, based on the total weight of the composition.

[0079] In one example of the topical skin preparation of the present invention, one or more moisturizers may be used. Moisturizers, also known as humectants, help enhance the effectiveness of emollients, reduce exfoliation, stimulate the removal of scaly skin, and improve skin feel. Polyols may be used as moisturizers, including, but not limited to, glycerin, polyalkylene glycols, alkylene polyols and their derivatives, including butylene glycol, propylene glycol, dipropylene glycol, glycerol, polyethylene glycol and their derivatives, sorbitol, hydroxypropyl sorbitol, hexanediol, 1,3-dibutylene glycol, 1,2,6-hexanetriol, ethoxylated glycerin, propoxylated glycerin, and combinations thereof. When used, the amount of moisturizer is from about 0.1% to about 20% by weight, preferably from about 1% to about 15% by weight, based on the total weight of the composition.

[0080] In one example of the topical skin formulation of the present invention, one or more emulsifiers may be used. The emulsifier may be used within a range of effective stable amounts. Preferably, the emulsifier is used at an amount of about 1.0 to about 10.0% by weight, more preferably about 3.0 to about 6.0% by weight, based on the total weight of the composition. Any emulsifier compatible with the components in the composition may be used. Suitable emulsifiers include stearic acid, cetyl alcohol, glyceryl stearate, lecithin, octadecyl alcohol, Steareth-2, Steareth-20, acrylate / C10-30 alkanol acrylate crosspolymers, and combinations thereof.

[0081] In one example of the topical skin formulation of the present invention, one or more pH adjusters may be used. Beneficial pH adjusters in the topical skin formulation of the present invention include tromethamine. When used, the amount of pH adjuster is approximately 0.1 to approximately 2% by weight, preferably approximately 0.1 to approximately 1% by weight, based on the total weight of the composition.

[0082] In one specific embodiment of the invention, the topical skin agent comprises an acrylate / C10-30 alkanol acrylate crosspolymer, glycerin, p-hydroxyacetophenone, glyceryl stearate and lecithin, cetearyl alcohol, cetearyl ethylhexanoate, tromethamine or a combination thereof.

[0083] In some embodiments of the present invention, the amount of oil composition in the topical skin agent is 0.001%-20% (w / w), preferably 0.01%-20% (w / w), more preferably 0.01%-10% (w / w), and most preferably 0.1%-5% (w / w).

[0084] In one specific embodiment of the present invention, the amount of the oil composition in the topical skin agent is 0.1-5% by weight. In a preferred embodiment, the amount of the oil composition in the topical skin agent is 0.13% by weight.

[0085] Example

[0086] The present invention will be further illustrated below with reference to specific embodiments. It is important to note that these embodiments are for illustrative purposes only and should not be construed as limiting the scope of protection of the invention. Those skilled in the art can make non-essential improvements and adjustments based on the above description of the invention. Test methods in the following embodiments that do not specify specific conditions are generally performed under conventional conditions or as recommended by the manufacturer. Unless otherwise stated, all percentages and parts are by weight.

[0087] Example 1: Component Detection of Fermented Artemisia annua Oil

[0088] (The method refers to the normalization method, the third method in GB 5009.168-2016)

[0089] Weigh 0.1 g to 10 g of fermented artemisia annua oil into a 250 mL flat-bottomed flask, add approximately 100 mg of pyrogallol, a few boiling chips, and 2 mL of 95% ethanol, and mix well. Add 10 mL of hydrochloric acid solution and mix well. Place the flask in a water bath at 70℃ to 80℃ for 40 min to hydrolyze. Shake the flask every 10 min to incorporate particles adhering to the flask wall into the solution. After hydrolysis, remove the flask and cool to room temperature. Add 8 mL of 2% sodium hydroxide methanol solution to the hydrolysate, connect a reflux condenser, and reflux in a water bath at 80℃ ± 1℃ until the oil droplets disappear. Add 7 mL of 15% boron trifluoride methanol solution from the top of the reflux condenser, and continue reflux in a water bath at 80℃ ± 1℃ for 2 min. Rinse the reflux condenser with a small amount of water. Stop heating, remove the flask from the water bath, and quickly cool to room temperature. Add 10 mL to 30 mL of n-heptane accurately, shake for 2 min, then add saturated sodium chloride aqueous solution and allow to stand for separation. Pipette approximately 5 mL of the upper n-heptane extract into a 25 mL test tube, add approximately 3 g to 5 g of anhydrous sodium sulfate, shake for 1 min, let stand for 5 min, and then pipette the upper solution into a sample vial for analysis.

[0090] Chromatographic determination: Single fatty acid methyl ester standard solutions and mixed fatty acid methyl ester standard solutions were injected separately into the gas chromatograph for qualitative analysis of the chromatographic peaks. Capillary column: Poly(dicyandipropylsiloxane) strongly polar stationary phase, column length 100 m, inner diameter 0.25 mm, film thickness 0.2 μm. Injector temperature: 270 ℃. Detector temperature: 280 ℃. Temperature program: Initial temperature 100 ℃, hold for 13 min; 100 ℃ ~ 180 ℃, ramp rate 10 ℃ / min, hold for 6 min; 180 ℃ ~ 200 ℃, ramp rate 1 ℃ / min, hold for 20 min; 200 ℃ ~ 230 ℃, ramp rate 4 ℃ / min, hold for 10.5 min. Carrier gas: Nitrogen. Split ratio: 100:1. Injection volume: 1.0 μL.

[0091] The percentage of a specific fatty acid in the total fatty acids in a sample, Yi, is calculated using the following formula. The content of a given component i is calculated by measuring the percentage of the corresponding peak area relative to the sum of the peak areas of all components:

[0092]

[0093] In the formula:

[0094] Y i —The percentage of a specific fatty acid in the total fatty acids in the sample, expressed as %.

[0095] A Si ———Peak areas of each fatty acid methyl ester in the sample test solution;

[0096] F FAMEi-FAi ——— The coefficient for the conversion of fatty acid methyl ester i into fatty acids;

[0097] ∑A Si ———The sum of the peak areas of each fatty acid methyl ester in the sample test solution.

[0098] The result should be rounded to 3 significant figures.

[0099] Test results show that batch 2 of fermented artemisia annua oil mainly contains oily components, with linoleic acid (cis-9,12-octadecadienoic acid) accounting for approximately 50%, which is considered a medium-to-high level among plant oils. Linoleic acid, an Omega-6 polyunsaturated fatty acid, is an essential component that the human body cannot synthesize on its own. Studies have found that linoleic acid has various effects in skincare, including improving the skin barrier, soothing inflammation, and anti-oxidation. The high linoleic acid content in fermented artemisia annua oil provides a material basis for its skincare effects. As the main component of fermented artemisia annua oil, when used as a product testing parameter, a relative content of linoleic acid ≥35% in the fatty acid composition of fermented artemisia annua oil meets the requirements. The results are shown in Tables 1-2.

[0100] Table 1

[0101]

[0102] Table 2: Fatty acid composition and relative content in fermented Artemisia annua oil

[0103]

[0104] HPLC method for determining the content of artemisinin in fermented artemisia annua oil

[0105] Experimental apparatus:

[0106] 1. Waters ARC high-performance liquid chromatograph with diode array detector (Waters);

[0107] 2. XS205 analytical balance (METTLER TOLEDO);

[0108] 3. KQ-800DE CNC ultrasonic cleaner (Kunshan Ultrasonic Instrument Co., Ltd.)

[0109] Chromatographic conditions:

[0110] Column: Agilent ZORBAX SB-C18, 250 mm × 4.6 mm × 5 μm;

[0111] Mobile phase: Acetonitrile (90%) - 0.1% phosphoric acid aqueous solution (10%);

[0112] Flow rate: 1.0 mL / min;

[0113] Column temperature: 30℃;

[0114] Wavelength: 220 nm;

[0115] Injection volume: 10 μL.

[0116] Testing steps:

[0117] Preparation of artemisinin standard stock solution (400 mg / L): Weigh 20 mg of artemisinin standard (Nature Standard, purity ≥98.0%) (accurate to 0.01 mg), dissolve in methanol and dilute to 50 mL.

[0118] Preparation and determination of artemisinin standard working solution: Accurately transfer 1 mL of artemisinin standard stock solution and dilute to 10 mL with methanol to obtain a standard working solution with a concentration of 40 mg / L. Perform the determination according to the chromatographic conditions described above.

[0119] Sample processing and determination:

[0120] Weigh 0.25 g (accurate to 0.1 mg) of the sample into a 10 mL stoppered colorimetric tube, add 8 mL of methanol, and extract by sonication for 20 min. Make up to volume with methanol, shake well, and filter the liquid fraction through a 0.45 μm filter membrane. Then, determine the chromatographic content according to the above conditions. Calculate the artemisinic acid content in the sample using the single-point external standard method.

[0121] The results are shown in Table 3.

[0122] Table 3

[0123]

[0124] As shown in the table above, all batches of fermented artemisia annua oil contained artemisinic acid, a characteristic component of artemisia annua, with a content greater than 0.03% by weight, which can be used as a characteristic indicator of fermented artemisia annua oil. Artemisinic acid is an important sesquiterpene compound extracted from artemisia annua (Artemisia annua), possessing various biological activities, including antimalarial activity, antipyretic effects, antibacterial and anti-inflammatory activities, and anti-glycation effects. The presence of a certain amount of artemisinic acid in fermented artemisia annua oil may be one of the reasons why fermented artemisia annua oil exhibits new therapeutic effects.

[0125] Acid value, peroxide value, and density testing

[0126] Detection method:

[0127] The acid value test method is based on GB / T 2716, the peroxide value test method is based on GB 5009.227-2023, and the density test method is based on GB / T 611.

[0128] The test results are shown in Table 4.

[0129] Table 4

[0130]

[0131] Example 2: Preparation of Selaginella tamariscina volatile oil (decolorized)

[0132] Selaginella tamariscina volatile oil was prepared according to the applicant's invention patent application CN202311861621.4.

[0133] This invention uses CO2 supercritical extraction to obtain the effective components of Selaginella tamariscina, and obtains Selaginella tamariscina volatile oil (decolorized) through processes such as filtration, decolorization, and concentration.

[0134] 1. Medicinal materials, instruments and reagents

[0135] Medicinal material: The raw herb Selaginella tamariscina (Beauv.) Spring was purchased in May 2023 from Xingzhi Pharmacy in Hehuachi Traditional Chinese Medicine Market, Sichuan Province. It is the dried whole herb of Selaginella tamariscina (Beauv.) Spring, a plant of the Selaginellaceae family.

[0136] Experimental instruments: Sample pulverizer (DFY-600C) purchased from Wenling Dade Pharmaceutical Machinery Co., Ltd.; vertical (double-layer) small full-temperature shaker (ZWY-2102C) purchased from Shanghai Zhicheng Analytical Instrument Manufacturing Co., Ltd.; refrigerated centrifuge (DL-5M) purchased from Shanghai Luxiangyi Centrifuge Instrument Co., Ltd.; enhanced rotary evaporator (R-200) purchased from Buchi GmbH, Switzerland; supercritical extraction equipment (RZSCF230-50-10L) purchased from Nantong Ruizhi Supercritical Technology Development Co., Ltd.

[0137] Reagents: Ethanol was purchased from Anhui Ante Food Co., Ltd., activated carbon was purchased from Sinopharm Chemical Reagent Co., Ltd., Xinxing brand qualitative filter paper (60cm*60cm) was purchased from Hangzhou Special Paper Co., Ltd., and sieves were purchased from Shanghai Yichang Instrument and Gauze Factory.

[0138] 2. Preparation of Selaginella tamariscina volatile oil (decolorized)

[0139] 1) After the whole Selaginella plant is dried, it is mechanically crushed using a pulverizer and then passed through a 20-mesh sieve.

[0140] 2) Weigh 956.89 g of Selaginella powder sample, add 1 L of 95% ethanol and mix, then put it into the extraction vessel of the CO2 supercritical extraction device.

[0141] 3) Perform supercritical CO2 extraction under the following conditions: extraction vessel pressure 25 MPa, extraction vessel temperature 45℃, CO2 flow rate 80 L / h, supercritical extraction time approximately 90 min; separation vessel I pressure 8 MPa, separation vessel I temperature 45℃; separation vessel II pressure 6 MPa, separation vessel II temperature 30℃; separation vessel III pressure 6 MPa, separation vessel III temperature 30℃.

[0142] 4) Extract until no sample comes out, collect the samples from separation vessel I and II, and let them stand overnight at 4°C.

[0143] 5) Centrifuge at 3℃ for 15 min at 3500 rpm. After centrifugation, filter the upper liquid through filter paper.

[0144] 6) Weigh the filtrate, calculate and add activated carbon equivalent to 1.5% of the filtrate weight, shake in a shaker at 50℃ and 200 rpm for 1 hour, centrifuge at 3℃ and 3500 rpm for 15 minutes, and filter with filter paper.

[0145] 7) Add the filtrate to a rotary evaporator at a temperature of 45-55℃ and concentrate the filtrate to an extract state to obtain Selaginella tamariscina volatile oil (decolorized).

[0146] Selaginella tamariscina volatile oil (decolorized) is a dark yellow solid oily substance.

[0147] Example 3:

[0148] Experimental materials:

[0149] Safflower seed oil: Shanghai Zhongrui Biotechnology Co., Ltd.;

[0150] Dibutyl adipic acid, BASF (China) Co., Ltd.;

[0151] Fermented Artemisia annua oil: purchased from Hangzhou Shiguang Xinya Biotechnology Co., Ltd.;

[0152] Selaginella oil: prepared in Example 2;

[0153] Mice with the SC57BL / 6J genetic background, Shanghai Jiao Tong University.

[0154] Experimental apparatus:

[0155] The ablative fractional laser (AFL) was performed using the Shanghai Laser LJL35-CS carbon dioxide laser therapy machine.

[0156] Experimental parameters: power: 20W, delay: 0.5ms, spacing (density): 0.7mm, size: 1cm x 1cm.

[0157] Experimental methods:

[0158] This experiment used 50-day-old C57BL / 6J mice in the hair resting phase. After shaving the hair on the back of the mice, hair removal cream was applied. The next day, an ablative fractional laser (AFL) was used on the back of the mice to simulate the effect of clinical laser treatment. The single-point energy was 10mJ, the interval was 0.7mm, and the area of ​​a single point was 15mm×15mm. The mice were randomly divided into 7 groups as follows: (I) Normal blank control group (no fractional laser, CON); (II) AFL control group (fractional laser, AFL group); (III) Sample group 1 AFL and 100 μl of safflower seed oil applied to the group (AFL + safflower seed oil); (IV) Sample group 2 AFL and 100 μl of fermented artemisia annua oil applied to the group (AFL + fermented artemisia annua oil); (V) Sample group 3 AFL and 100 μl of dibutyl adipate applied to the group (AFL + dibutyl adipate); (VI) Sample group 4 AFL and 100 μl of dibutyl adipate + selaginella oil applied to the group (AFL + dibutyl adipate + selaginella oil); (VII) Sample group 5 AFL and 100 μl of safflower seed oil + fermented artemisia annua oil + selaginella oil applied to the group (AFL + safflower seed oil + fermented artemisia annua oil + selaginella oil = 1000:1000:1). After fractional laser treatment on the backs of mice, samples were applied twice daily, 100 μL each time, with a 12-hour interval, for 7 consecutive days. Mice were photographed and their TEWL changes were assessed using a GPSkin device at 12h, 24h, 48h, 72h, 5 days, and 7 days after AFL treatment, with oil applied once daily.

[0159] Experimental results:

[0160] Table 5 shows the experimental group information.

[0161] Table 5

[0162]

[0163] Before applying the oil at 12h, 24h, 36h, 48h, 5 days and 7 days after AFL in mice, the changes in TEWL on the back skin of mice were tested using a GPSkin device. Three locations on the back of each mouse were randomly selected for testing and statistical analysis.

[0164] Figures 1-6 The results of changes in TEWL in mice assessed using the GPSkin device at 12h, 24h, 36h, 48h, 5 days, and 7 days are shown.

[0165] As shown in the figure, after fractional laser treatment, compared with the AFL group, samples 1, 2, 4, 5, and 6 all alleviated the increase in TEWL caused by fractional laser treatment, indicating that the samples have the effect of promoting post-fractional laser repair; among them, sample 5 was the best, indicating that it has a good effect of promoting post-fractional laser repair.

[0166] At 12h, 24h, 36h, 48h, 5 days and 7 days after fractional laser treatment, compared with the AFL group, samples 1, 2, 4, 5 and 6 all alleviated the increase in TEWL caused by fractional laser treatment, indicating that the samples promoted the repair after fractional laser treatment. At 24h and 36h, sample group 2, sample group 5 and sample group 6 were relatively optimal. On day 7, sample 5 was the best, indicating that it had a good effect on promoting the repair after fractional laser treatment.

[0167] The results showed that sample group 5 significantly reduced transdermal water loss in the mouse epidermis in the laser-induced repair model.

[0168] Because Selaginella oil has poor solubility and is an oily component, various substances were used to dissolve and dilute Selaginella oil. It was found that the solubility in non-vegetable oils with strong polarity, such as dibutyl adipate, nonionic surfactant Tween-20, safflower seed oil, and fermented artemisia annua oil, can reach 0.1%.

[0169] To ensure the accuracy of efficacy experiments, it was necessary to select a non-plant oil solvent that had no repairing effects and did not damage the skin barrier. The results showed that, compared to Tween-20, dibutyl adipate, while maintaining the solubility of Selaginella tamariscina oil, did not alleviate the increase in transdermal water loss in the mouse fractional laser model, had no repairing effects, and did not damage the skin barrier. Therefore, it is a good solvent for Selaginella tamariscina oil and a control solvent for the experiment.

[0170] Figure 7 The results show the effects of applying butyl adipate or Tween 20 to mice on days 1-3 after fractional laser treatment. The results indicate that butyl adipate has no skin-repairing or barrier-damaging effect on the mouse fractional laser model.

[0171] Figure 8 This study shows the changes in transepidermal water loss (TEWL) in mice assessed using a GPSkin device on days 1-3 after fractional laser treatment followed by application of either butyl adipic acid adipate or Tween 20. The results indicate that butyl adipic acid adipate did not alleviate the increase in transepidermal water loss in the mouse fractional laser model.

[0172] The oil composition described in this invention can be used as a functional additive in topical skin agents, preferably cosmetic compositions, including but not limited to the preparation of products in dosage forms such as creams, lotions, gels, toners, serums, masks, eye creams, aerosols (cleansing foams), shower gels, and facial cleansers. The oil composition constitutes 0.0001%-100% (w / w) of the topical skin agent by weight. A preferred weight percentage is 0.001%-20% (w / w). A more preferred weight percentage is 0.001%-10% (w / w). The most preferred weight percentage is 0.01%-5% (w / w).

[0173] The following are specific examples of the application of oil-based compositions in topical skin preparations, along with the formulations and preparation methods of these dosage forms. Specific applications are as follows:

[0174] Application Example 1: Preparation of Face Cream

[0175]

[0176] Application Example 2: Emulsion Preparation

[0177]

[0178] Application Example 3: Preparation of Eye Cream

[0179]

[0180] Application Example 4: Preparation of Facial Masks

[0181]

[0182] Application Example 5: Preparation of Serum

[0183]

[0184] Application Example 6: Preparation of Essential Oils

[0185]

Claims

1. Oil composition comprising safflower seed oil, fermented artemisia oil and selaginella oil for post-medical aesthetic treatment, characterized in that, The fermented artemisia oil is prepared by the following method: (a) using artemisia medicinal materials for supercritical CO2 extraction; (b) fermentation, using bifida fermentation; (c) after separation, fermented artemisia oil is obtained; The bifida is bifidobacterium, selected from: bifidobacterium adolescentis, bifidobacterium animalis animalis subsp, bifidobacterium animalis lactis subsp, bifidobacterium bifidum, bifidobacterium breve, bifidobacterium longum longum subsp, or bifidobacterium longum infantis subsp.

2. Use according to claim 1, wherein The content of artemisinic acid in the fermented artemisia oil is ≥ 0.03% by weight, the acid value of the fermented artemisia oil is ≤ 2.5 mg / g, the peroxide value of the fermented artemisia oil is ≤ 0.650 g / 100 g, the density of the fermented artemisia oil is 0.9-0.95 g / cm 3 .

3. The use according to claim 1, wherein The weight ratio of safflower seed oil: fermented artemisia oil: selaginella oil in the oil composition is 1000-2000: 1000-2000:

1.

4. The use according to claim 1, wherein The medical art after is caused by dot matrix laser.

5. The use according to claim 1, wherein The repair includes reducing the skin TEWL change after medical art.

6. Use of an oil composition comprising safflower seed oil, fermented artemisia oil, and selaginella oil in the preparation of a skin external agent having a medical and aesthetic post-treatment repairing effect, characterized in that, The fermented artemisia oil is prepared by the following method: (a) using artemisia medicinal materials for supercritical CO2 extraction; (b) fermentation, using bifida fermentation; (c) after separation, fermented artemisia oil is obtained; The bifida is bifidobacterium, selected from: bifidobacterium adolescentis, bifidobacterium animalis animalis subsp, bifidobacterium animalis lactis subsp, bifidobacterium bifidum, bifidobacterium breve, bifidobacterium longum longum subsp, or bifidobacterium longum infantis subsp.

7. Use according to claim 6, wherein the compound is ###0003### The weight ratio of safflower seed oil: fermented artemisia oil: selaginella oil in the oil composition is 1000-2000: 1000-2000:

1.

8. The use according to claim 6, wherein the compound is ###0002### The content of the oil composition in the skin external preparation is 0.001-100% by weight.

9. The use according to claim 6, wherein the compound is ###0003### The content of the oil composition in the skin external preparation is 0.01-5% by weight.

10. The use according to claim 6, wherein The skin external preparation is selected from: face cream, emulsion, jelly, cosmetic water, essence, mask, eye cream, aerosol cleaning foam, spray, shower gel, or facial cleanser.

Images